Live GMP
Aureate Tradde Ltd GMP ₹0 SMR Jewels Ltd GMP ₹0 Rajnandini Fashion India Ltd GMP ₹11+17.46% Hexagon Nutrition Ltd GMP ₹3+6.67% Genxai Analytics Ltd GMP ₹0 Vahh Chemicals Ltd GMP ₹0 CMR Green Technologies Ltd GMP ₹0 Merritronix Ltd GMP ₹93+62.42% Liotech Industries Ltd. GMP ₹0
Dr.Agarwal's Health Care Ltd. Logo

Dr.Agarwal's Health Care Ltd. IPO

Closed Bookbuilding IPO NSE & BSE Fresh Capital-cum-Offer for Sale
← Back to GMP
Issue Price ₹402
GMP
Lot Size 35
Face Value ₹1
Issue Size 75,304,970 shares (aggregating up to ₹3,027 Cr)
Subscription

IPO Timeline

Open Date29-Jan-25
Close Date31-Jan-25
Allotment3-Feb-25
Refund Initiation4-Feb-25
Demat Credit4-Feb-25
UPI Mandate Deadline31-Jan-25
Listing Date4-Feb-25
Lock-in (30%)2-Mar-25
Lock-in (50%)1-May-25

Category-wise Subscription

Shares offered, bid & amount
CategorySub (x)OfferedBid ForAmt (Cr)*
QIB 36,297,998 (48%) ₹145,918 Cr
NII (HNI) 10,889,400 (14%) ₹43,775 Cr
Retail 25,408,599 (34%) ₹102,143 Cr
Employee 1,579,399 (2%) ₹635 Cr
Σ  Total75,304,970 (100%)₹3,027,260 Cr

Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.

Issue Details

Issue Price / Price Band₹402
Face Value₹1
Lot Size35 shares
Issue Size75,304,970 shares (aggregating up to ₹3,027 Cr)
Issue TypeBookbuilding IPO
Listing ExchangeNSE & BSE
Sale TypeFresh Capital-cum-Offer for Sale
Script Code
Fresh Issue7,462,686 shares (aggregating up to ₹300 Cr)
Offer for Sale67,842,284 shares of ₹1 (aggregating up to ₹2,727 Cr)
Net Offer to Public
Amount In₹ Crore
Stock Price History · BSE
Loading chart data...
H
L
O
Yahoo Finance · Live

Minimum Investment (Lot-wise)

CategoryLotsSharesAmount (₹)
Retail (Min)135₹14,070
Retail (Max)13455₹182,910
S-HNI (Min)14490₹196,980
B-HNI (Min)672,345₹942,690
Retail1 lot(s)35 shares₹14,070
S-HNI72 lot(s)2,520 shares₹1,013,040

Shareholding Pattern

Pre-Issue Shareholding308,417,160 shares%
Post-Issue Shareholding315,879,846 shares%
Reserved for Market Maker

Financial Statements Amount in ₹ Crore

Metric 30 Sep 2024 31 Mar 2024 31 Mar 2023
Revenue 838 1,376 1,031
Profit After Tax 40 95 103
Net Worth 1,503 1,338 628
Total Assets 3,393 2,753 1,825
Reserves & Surplus 1,509 1,366 653
Total Borrowing 374 388 356

Valuation & Key Ratios

ROE9%
ROCE15%
RONW6%
PAT Margin7%
EBITDA Margin
Debt/Equity
P/BV8
Pre EPS₹3
Post EPS₹3
Pre P/E130
Post P/E160

Grey Market Premium (GMP)

Current GMP

GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.

Objects of the Issue

  • Repayment/prepayment, in part or full, of certain of the borrowings –
  • General corporate purposes and unidentified inorganic acquisition. –

Company Overview

Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.

As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.

The Services provided by the company are:-

Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;

Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).

Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.

As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).

As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.

Competitive Strength

  • Largest eye care services provider in India with a trusted brand
  • End-to-end, comprehensive eye care services offering
  • Scalable, asset-light, hub-and-spoke operating model
  • Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations. 
  • Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
  • Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability

Company Information

Address1 st Floor, Buhari Towers No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai 600 006 Chennai, Tamil Nadu